Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma.
Hoshi Y, Enokida T, Tamura S, Nakashima T, Okano S, Fujisawa T, Sato M, Wada A, Tanaka H, Takeshita N, Tanaka N, Onaga R, Kishida T, Uryu H, Sakashita S, Asakage T, Tahara M. Hoshi Y, et al. Among authors: onaga r. Front Oncol. 2024 May 23;14:1379013. doi: 10.3389/fonc.2024.1379013. eCollection 2024. Front Oncol. 2024. PMID: 38846982 Free PMC article.
Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Takeshita N, Enokida T, Okano S, Fujisawa T, Wada A, Sato M, Tanaka H, Tanaka N, Onaga R, Hoshi Y, Sakashita S, Ishii G, Tahara M. Takeshita N, et al. Among authors: onaga r. Oral Oncol. 2023 Dec;147:106615. doi: 10.1016/j.oraloncology.2023.106615. Epub 2023 Nov 4. Oral Oncol. 2023. PMID: 37931493
Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck.
Tanaka H, Enokida T, Okano S, Fujisawa T, Tanaka N, Takeshita N, Onaga R, Hoshi Y, Wada A, Sato M, Ueda Y, Tahara M. Tanaka H, et al. Among authors: onaga r. Front Oncol. 2023 Nov 21;13:1221352. doi: 10.3389/fonc.2023.1221352. eCollection 2023. Front Oncol. 2023. PMID: 38074688 Free PMC article.
Successful Preoperative QUAD SHOT for Bulky Parotid Carcinoma: Potential Preoperative Ultra-Hypofractionated Radiotherapy for Conversion Surgery.
Takahashi S, Endo M, Nagatomo T, Onaga R, Yamaguchi H, Yamamoto R, Fukuda Y, Ogawa K, Nakamura M, Okada K, Akahane K, Kawahara M, Nishino H, Kanazawa T, Mori H, Shirai K. Takahashi S, et al. Among authors: onaga r. Case Rep Oncol. 2023 Apr 14;16(1):218-226. doi: 10.1159/000529829. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 37069898 Free PMC article.
Clinical Outcomes of Radiotherapy for Stage 1 Glottic Carcinoma: Comparing Accelerated Hyperfractionation and Once-daily Fractionation.
Endo M, Fukuda Y, Okada K, Ogawa K, Nakamura M, Takahashi S, Murakami E, Shibayama C, Kawahara M, Akahane K, Onaga R, Nagatomo T, Kanazawa T, Nishino H, Mori H, Shirai K. Endo M, et al. Among authors: onaga r. In Vivo. 2023 Sep-Oct;37(5):2320-2326. doi: 10.21873/invivo.13335. In Vivo. 2023. PMID: 37652523 Free PMC article.
The association between initiation weekday of radiotherapy and local control in stage 1 glottic carcinoma: a retrospective analysis.
Endo M, Takahashi S, Fukuda Y, Okada K, Ogawa K, Nakamura M, Kawahara M, Akahane K, Murakami E, Shibayama C, Onaga R, Nagatomo T, Kanazawa T, Nishino H, Mori H, Shirai K. Endo M, et al. Among authors: onaga r. J Radiat Res. 2024 Dec 3;65(6):798-804. doi: 10.1093/jrr/rrae074. J Radiat Res. 2024. PMID: 39287117 Free PMC article.
12 results